person · Reporting owner

FOLETTA MARK G

Disclosed activity across 5 companies

Tapewire entity: 26831
SEC CIK: 0001236389

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMN HEALTHCARE SERVICES INCAMN · Entity 4780	Director	June 15, 2026	June 17, 2026
DEXCOM INCDXCM · Entity 3114	Director	July 31, 2026	August 04, 2026
ENANTA PHARMACEUTICALS INCENTA · Entity 5673	Director	March 11, 2026	March 13, 2026
Forte Biosciences, Inc.TOCA · Entity 9529	EVP & Chief Financial Officer	October 04, 2019	October 05, 2019
Regulus Therapeutics Inc.RGLS · Entity 78034	Director	December 04, 2017	December 07, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMN HEALTHCARE SERVICES INC

Report date June 15, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Trust	17,917	Last balance in matching sequence After 2026-06-15 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-06-15 · Sale · Disposed 1,681 · Balance 19,917 F1: The sale of 1,681 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F2: The price reported in this row represents a weighted average price of $31.067 per share. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Row 2 · 2026-06-15 · Sale · Disposed 2,000 · Balance 17,917 F4: The sale of 2,000 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F5: The price reported in this row represents a weighted average price of $31.069 per share. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The sale of 1,681 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan").

F2: The price reported in this row represents a weighted average price of $31.067 per share. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

F4: The sale of 2,000 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan").

F5: The price reported in this row represents a weighted average price of $31.069 per share. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

DEXCOM INC

Report date July 31, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Trust	48,852	Last balance in matching sequence After 2026-08-03 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-07-31 · Sale · Disposed 2,000 · Balance 50,852 F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Row 2 · 2026-08-03 · Sale · Disposed 2,000 · Balance 48,852 F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
Common StockSEC Table I · non-derivative	Direct	6,331	Reported balance Holding disclosure · report date 2026-07-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 6,331 F3: Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

F3: Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

ENANTA PHARMACEUTICALS INC

Report date March 11, 2026 · Filed March 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11	Direct	20,000	Reported balance After 2026-03-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

Forte Biosciences, Inc.

Report date October 04, 2019 · Filed October 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03	Direct	30,000	Reported balance After 2019-10-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-10-04 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.

Regulus Therapeutics Inc.

Report date December 04, 2017 · Filed December 07, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	81,910	Reported balance After 2017-12-04 transaction · row 1 1 source row Row 1 · 2017-12-04 · Grant · Acquired 71,910 · Balance 81,910 F1: Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $64,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $64,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 14, 2020 Filed Sep 16, 2020 20:44 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	114	$397.75	$45,343.71	Disclosure SEC source: 0001093557-20-000261 · edgardoc.xml · nonDerivative · entry 7 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,202 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $397.385 to $397.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:44 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	121	$396.17	$47,936.19	Disclosure SEC source: 0001093557-20-000261 · edgardoc.xml · nonDerivative · entry 6 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,316 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $395.795 to $396.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:44 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	222	$395.28	$87,752.63	Disclosure SEC source: 0001093557-20-000261 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,437 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $394.78 to $395.635. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:44 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	231	$393.73	$90,951.19	Disclosure SEC source: 0001093557-20-000261 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,659 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $393.41 to $394.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:44 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	200	$391.95	$78,389.68	Disclosure SEC source: 0001093557-20-000261 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,890 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $391.585 to $392.745. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:44 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	109	$390.86	$42,603.52	Disclosure SEC source: 0001093557-20-000261 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,090 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $390.475 to $391.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:44 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	3	$386.21	$1,158.63	Disclosure SEC source: 0001093557-20-000261 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,199 F1 · shares: On June 6, 2020, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
June 29, 2020 Filed Jul 1, 2020 23:19 UTC	ENANTA PHARMACEUTICALS INC ENTA · Entity 5673	GrantStock Option (right to buy) · Derivative	17,000	$0.00 Strike: $49.04	$0.00	Disclosure SEC source: 0001177648-20-000029 · edgar.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2030-06-29 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over three years, beginning from the date of grant (June 29, 2020). Read SEC document
May 22, 2020 Filed May 27, 2020 21:49 UTC	DEXCOM INC DXCM · Entity 3114	GrantCommon Stock	895	$0.00	$0.90	Disclosure SEC source: 0001093557-20-000168 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895 F2 · shares: The RSU Award was granted on May 22, 2020 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2021 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 895 restricted stock units which were granted on May 22, 2020 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2021 Annual Meeting. Read SEC document
May 21, 2020 Filed May 27, 2020 21:49 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	3,055	$0.00	$0.00	Disclosure SEC source: 0001093557-20-000168 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,202 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. F4 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
May 21, 2020 Filed May 27, 2020 21:49 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	3,055	$0.00	$0.00	Disclosure SEC source: 0001093557-20-000168 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document
April 22, 2020 Filed Apr 24, 2020 17:45 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	GrantRestricted Stock Units · Derivative	2,826	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025560 · doc4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,826 Underlying: Common Stock · 2,826 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units identified in this row were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each Restricted Stock Unit represents a contingent right to receive one share of AMN Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units identified in this row were granted on April 22, 2020 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's 2021 Annual Meeting of Shareholders. F3 · derivative.expiration_date: Restricted Stock Units do not have an expiration date. Read SEC document
April 17, 2020 Filed Apr 21, 2020 19:51 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionRestricted Stock Units · Derivative	2,907	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025205 · doc4.xml · derivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F3 · derivative.exercise_date: The RSUs were granted on April 17, 2019 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's 2020 Annual Meeting of Shareholders. Accordingly, the number of RSUs identified in this row vested on April 17, 2020. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document
April 17, 2020 Filed Apr 21, 2020 19:51 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionCommon Stock	2,907	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025205 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: AMN Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	84	$288.26	$24,213.84	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 11 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,147 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	75	$285.48	$21,411.06	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 10 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,231 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $285.445 to $286.34. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	84	$282.77	$23,752.68	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 9 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,306 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	53	$281.61	$14,925.07	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 8 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,390 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	31	$279.60	$8,667.57	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 7 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,443 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $278.985 to $279.935. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	64	$277.48	$17,758.81	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 6 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,474 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $276.70 to $277.62. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	114	$275.56	$31,413.97	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,538 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $275.385 to $275.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	155	$274.88	$42,606.93	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,652 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $274.195 to $275.185. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	81	$272.82	$22,098.42	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,807 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	152	$271.54	$41,273.97	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,888 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $271.37 to $271.68. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
March 03, 2020 Filed Mar 4, 2020 23:42 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	107	$270.63	$28,957.00	Disclosure SEC source: 0001093557-20-000045 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,040 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $270.04 to $271.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
February 03, 2020 Filed Feb 5, 2020 23:04 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	9	$240.68	$2,166.09	Disclosure SEC source: 0001093557-20-000017 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,147 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $240.495 to $241.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
February 03, 2020 Filed Feb 5, 2020 23:04 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	166	$238.86	$39,650.16	Disclosure SEC source: 0001093557-20-000017 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,156 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $238.81 to $238.905. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
February 03, 2020 Filed Feb 5, 2020 23:04 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	524	$238.05	$124,736.47	Disclosure SEC source: 0001093557-20-000017 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,322 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $237.60 to $238.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
February 03, 2020 Filed Feb 5, 2020 23:04 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	301	$236.84	$71,290.25	Disclosure SEC source: 0001093557-20-000017 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,846 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $236.585 to $237.03. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
January 03, 2020 Filed Jan 8, 2020 01:49 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	133	$218.94	$29,118.42	Disclosure SEC source: 0001093557-20-000005 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,147 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $218.86 to $219.06. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
January 03, 2020 Filed Jan 8, 2020 01:49 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	339	$218.39	$74,035.33	Disclosure SEC source: 0001093557-20-000005 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,280 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $217.80 to $218.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
January 03, 2020 Filed Jan 8, 2020 01:49 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	528	$217.61	$114,899.14	Disclosure SEC source: 0001093557-20-000005 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,619 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $216.79 to $217.77. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 03, 2019 Filed Dec 5, 2019 21:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	462	$228.93	$105,766.49	Disclosure SEC source: 0001093557-19-000253 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,147 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $228.46 to $229.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 03, 2019 Filed Dec 5, 2019 21:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	233	$227.66	$53,045.64	Disclosure SEC source: 0001093557-19-000253 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,609 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $227.16 to $228.09. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 03, 2019 Filed Dec 5, 2019 21:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	232	$226.20	$52,478.45	Disclosure SEC source: 0001093557-19-000253 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,842 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $225.615 to $226.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 03, 2019 Filed Dec 5, 2019 21:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	70	$223.41	$15,638.70	Disclosure SEC source: 0001093557-19-000253 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,074 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
December 03, 2019 Filed Dec 5, 2019 21:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	3	$221.34	$664.02	Disclosure SEC source: 0001093557-19-000253 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,144 F1 · shares: On August 30, 2019, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
October 04, 2019 Filed Oct 5, 2019 00:38 UTC	Forte Biosciences, Inc. TOCA · Entity 9529	GrantEmployee Stock Option (right to buy) · Derivative	30,000	$0.00 Strike: $0.64	$0.00	Disclosure SEC source: 0001209191-19-052622 · doc4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document
May 31, 2019 Filed Jun 4, 2019 23:55 UTC	DEXCOM INC DXCM · Entity 3114	GrantCommon Stock	3,055	$0.00	$3.06	Disclosure SEC source: 0001093557-19-000148 · wf-form4_155969251078133.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,055 F3 · shares: The RSU Award was granted on May 31, 2019 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2020 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F4 · balance_after: Represents 3,055 restricted stock units which were granted on May 31, 2019 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2020 Annual Meeting. Read SEC document
May 30, 2019 Filed Jun 4, 2019 23:55 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	4,052	$0.00	$0.00	Disclosure SEC source: 0001093557-19-000148 · wf-form4_155969251078133.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,147 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
May 30, 2019 Filed Jun 4, 2019 23:55 UTC	DEXCOM INC DXCM · Entity 3114	OtherCommon Stock	4,052	$0.00	$0.00	Disclosure SEC source: 0001093557-19-000148 · wf-form4_155969251078133.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document
May 28, 2019 Filed May 29, 2019 20:29 UTC	Forte Biosciences, Inc. TOCA · Entity 9529	PurchaseCommon Stock	5,000	$4.30	$21,475.00	Disclosure SEC source: 0001209191-19-033196 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,042 F1 · price: The weighted average purchase price for the transaction reported was $4.295, and the range of prices were between $4.2245 and $4.3509. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · balance_after: Includes 1,373 shares of Common Stock that were acquired by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan and 1,169 shares of Common Stock that were acquired by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
May 15, 2019 Filed May 17, 2019 22:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	400	$122.73	$49,090.52	Disclosure SEC source: 0001093557-19-000125 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,095 F1 · shares: On December 13, 2018, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $122.49 to $122.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
May 15, 2019 Filed May 17, 2019 22:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	500	$121.88	$60,939.00	Disclosure SEC source: 0001093557-19-000125 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,495 F1 · shares: On December 13, 2018, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $121.35 to $122.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
May 15, 2019 Filed May 17, 2019 22:22 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	100	$118.65	$11,865.00	Disclosure SEC source: 0001093557-19-000125 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,995 F1 · shares: On December 13, 2018, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
April 17, 2019 Filed Apr 19, 2019 19:55 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	GrantRestricted Stock Units · Derivative	2,907	$0.00	$0.00	Disclosure SEC source: 0001209191-19-025368 · doc4.xml · derivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,907 Underlying: Common Stock · 2,907 shares Expires not disclosed F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F5 · derivative.exercise_date: The RSUs were granted on April 17, 2019 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's 2020 Annual Meeting of Shareholders. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document
April 17, 2019 Filed Apr 19, 2019 19:55 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionRestricted Stock Units · Derivative	2,153	$0.00	$0.00	Disclosure SEC source: 0001209191-19-025368 · doc4.xml · derivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,153 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F3 · derivative.exercise_date: The RSUs were granted on April 18, 2018 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's 2019 Annual Meeting of Shareholders. The Company's 2019 Annual Meeting of Shareholders was held on April 17, 2019. Accordingly, the number of RSUs identified in this row (2,153) vested on April 17, 2019. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document
April 17, 2019 Filed Apr 19, 2019 19:55 UTC	AMN HEALTHCARE SERVICES INC AMN · Entity 4780	Exercise / conversionCommon Stock	2,153	$0.00	$0.00	Disclosure SEC source: 0001209191-19-025368 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document
April 15, 2019 Filed Apr 17, 2019 21:20 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	599	$119.36	$71,496.58	Disclosure SEC source: 0001093557-19-000100 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,095 F1 · shares: On December 13, 2018, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $119.05 to $119.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document
April 15, 2019 Filed Apr 17, 2019 21:20 UTC	DEXCOM INC DXCM · Entity 3114	SaleCommon Stock	301	$118.88	$35,783.99	Disclosure SEC source: 0001093557-19-000100 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,694 F1 · shares: On December 13, 2018, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $118.00 to $119.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.